Autoantibodies to the nucleolar phosphoprotein nucleophosmin in breast cancer patients

Cancer Epidemiology Biomarkers and Prevention

Volumn 7, Issue 12, 1998, Pages 1109-1115

  Brankin, Brenda ^a   Skaar, Todd C ^a   Brotzman, Michelle ^a   Trock, Bruce ^a   Clarke, Robert ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; NUCLEAR PROTEIN; NUCLEOPHOSMIN; PHOSPHOPROTEIN; ESTROGEN; TUMOR MARKER;

ADULT; ANTIBODY DETECTION; ARTICLE; BREAST CANCER; CANCER RECURRENCE; CONTROLLED STUDY; DISEASE ASSOCIATION; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; STATISTICAL ANALYSIS; ANALYSIS OF VARIANCE; BLOOD; BREAST TUMOR; CASE CONTROL STUDY; FEMALE; IMMUNOLOGY; MIDDLE AGED; NEOPLASM; PILOT STUDY; RISK; TUMOR RECURRENCE;

ADULT; ANALYSIS OF VARIANCE; AUTOANTIBODIES; BREAST NEOPLASMS; CASE-CONTROL STUDIES; ESTROGENS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, HORMONE-DEPENDENT; NUCLEAR PROTEINS; ODDS RATIO; PHOSPHOPROTEINS; PILOT PROJECTS; TUMOR MARKERS, BIOLOGICAL;

EID: 0032217255     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Lee, Y. Carcinoembryonic antigen as a monitor of recurrent breast cancer. J. Surg. Oncol., 20: 109-112, 1982.
2. Hayes, D. F., Zurawski, V. R., and Kufe, D. W. Comparison of circulating CA15-3 and Carcinoembryonic antigen levels patients with breast cancer. J. Clin. Oncol., 4: 1542-1550, 1986.
3. Willsher, P. C., Beaver, J., Finder, S., Bell, J. A., Ellis, I. O., Blamey, R. W., and Robertson, J. F. R. Prognostic significance of serum c-erbB-2 protein in breast cancer patients. Breast Cancer Res. Treat., 40: 251-255, 1996.
4. Vojtesek, B., Kovarik, J., Dolezalova, H., Nenutil, R., Havlis, P., Brentani, R. R., and Lane, D. P. Absence of p53 autoantibodies in a significant proportion of breast cancer patients. Br. J. Cancer, 71: 1253-1256, 1995.
5. Hayes, D. F., and Kaplan, W. Evaluation of patients after primary therapy. In: J. R. Harris, M. E. Lippman, M. Morrow, and S. Hellman (eds.), Diseases of the Breast, pp. 629-647. Philadelphia: Lippincott-Raven, 1996.
6. Harris, J. R., Morrow, M., and Bonadonna, G. Cancer of the breast. In: V. T. DeVita, S. Hellman, and S. A. Rosenberg (eds.), Cancan Principles & Practice of Oncology, pp. 1264-1332. Philadelphia: J. B. Lippincott Co., 1993.
7. Dickson, R. B., Low, J. A., Johnson, J. D., Hawkins, M. J., and Trock, B. J. Blood-borne indicators of breast cancer and their use in experimental, medical oncologic and prevention studies. Breast, 5: 379-384, 1996.
8. Clarke, R., Brünner, N., Katzenellenbogen, B. S., Thompson, E. W., Norman, M. J., Koppi, C., Paik, S., Lippman, M. E., and Dickson, R. B. Progression from hormone dependent to hormone independent growth in MCF-7 human breast cancer cells. Proc. Natl. Acad. Sci. USA, 86: 3649-3653, 1989.
9. Brünner, N., Frandsen, T. L., Holst-Hansen, C., Bei, M., Thompson, E. W., Wakeling, A. E., Lippman, M. E., and Clarke, R. MCF7/LCC2: a 4-hydroxytamoxifen-resistant human breast cancer variant which retains sensitivity to the steroidal antiestrogen ICI 182,780. Cancer Res., 53: 3229-3232, 1993.
10. Clarke, R., Skaar, T., Baumann, K., Leonessa, K., James, M. R., Lippman, J., Thompson, E. W., Freier, C., and Brünner, N. Hormonal carcinogenesis in breast cancer: cellular and molecular studies of malignant progression. Breast Cancer Res. Treat., 31: 237-248, 1994.
11. Skaar, T., Brünner, N., Lippman, M. E., and Clarke, R. Numatrin expression increases as breast cancer cells progress to estrogen independence and antiestrogen resistance. Proc. Am. Assoc. Cancer Res., 37: 225, 1996.
12. Morris, S. W., Kirstein, M. N., Valentine, M. B., Dittmer, K. G., Shapiro, D. N., Saltman, D. L., and Look, A. T. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodskin's lymphoma. Science (Washington DC), 263: 1281-1284, 1994.
13. Redner, R. L., Rush, E. A., Faas, S., Rudert, W. A., and Corey, S. J. The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion. Blood, 87: 882-886, 1996.
14. Hernandez-Verdun, D. The nucleus today. J. Cell Sci., 99: 465-471, 1991.
15. Feuerstein, N., Mond, J. J., Kinchington, P. R., Hickey, R., Karjalainen Lindsberg, M. L., Hay, L., and Ruyechan, W. T. Evidence for DNA binding activity of numatrin (B23), a cell cycle-regulated nuclear matrix protein. Biochim. Biophys. Acta, 1087: 127-136, 1990.
16. Inouye, C. J., and Seto, E. Relief of YY1-induced transcriptional repression by protein-protein interaction with the nucleolar phosphoprotein B23. J. Biol. Chem., 269: 6506-6510, 1994.
17. Meier, V. S., and Groner, B. The nuclear factor YY1 participates in repression of the β-casein gene promoter in mammary epithelial cells and is counter-acted by mammary gland factor during lactogenic hormone induction. Mol. Cell. Biol., 14: 128-137, 1994.
18. Yim, J. H., Wu, S. J., Casey, M. J., Norton, J. A., and Doherty, G. M. IFN regulatory factor-1 gene transfer into an aggressive, nonimmunogenic sarcoma suppresses the malignant phenotype and enhances immunogenicity in syngeneic mice. Hokkaido Igaku Zasshi, 71: 509-516, 1997.
19. Kondo, T. Identification and analysis of IRF-1 binding protein. Hokkaido Igaku Zasshi, 71: 509-516, 1996.
20. Beckmann, R., Buchner, K., Jungblut, P. R., Eckerskorn, C., Weise, C., Hubert, R., and Hucho, F. Nuclear substrates of protein kinase C. Eur. J. Biochem., 210: 45-51, 1992.
21. Peter, M., Nakagawa, J., Doree, M., Labbe, J. C., and Nigg, E. A. Identification of major nucleolar proteins as candidate mitotic substrates of cdc2 kinase. Cell, 60: 791-801, 1990.
22. Feuerstein, N., and Randazzo, P. A. In vivo and in vitro phosphorylation studies of numatrin, a cell cycle regulated nuclear protein, in insulin-stimulated NIH 3T3 HIR cells. Exp. Cell Res., 194: 289-296, 1991.
23. Chan, P. K., Liu, Q. R., and Durban, E. The major phosphorylation site of nucleophosmin (B23) is phosphorylated by a nuclear kinase II. Biochem. J., 270: 549-552, 1990.